Cargando…

Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: post hoc analysis of phase III trials using patient-reported outcomes

BACKGROUND: Pain is a common symptom of hemophilia that may adversely affect patients’ quality of life (QoL). Previous post hoc analyses of prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) have been published for adults and adolescents, demonstrating improvements in health-related Q...

Descripción completa

Detalles Bibliográficos
Autores principales: Astermark, Jan, Hermans, Cédric, Ezzalfani, Monia, Sidhom, Alaeddine, Barbier, Sylvaine, Kragh, Nana, Falk, Aletta, Eriksson, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240555/
https://www.ncbi.nlm.nih.gov/pubmed/37283819
http://dx.doi.org/10.1177/20406207231170701
_version_ 1785053788522938368
author Astermark, Jan
Hermans, Cédric
Ezzalfani, Monia
Sidhom, Alaeddine
Barbier, Sylvaine
Kragh, Nana
Falk, Aletta
Eriksson, Daniel
author_facet Astermark, Jan
Hermans, Cédric
Ezzalfani, Monia
Sidhom, Alaeddine
Barbier, Sylvaine
Kragh, Nana
Falk, Aletta
Eriksson, Daniel
author_sort Astermark, Jan
collection PubMed
description BACKGROUND: Pain is a common symptom of hemophilia that may adversely affect patients’ quality of life (QoL). Previous post hoc analyses of prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) have been published for adults and adolescents, demonstrating improvements in health-related QoL (HRQoL) when assessed by the haemophilia-specific QoL (HaemAQoL) questionnaire. OBJECTIVE: To describe in depth the evolution of QoL, pain- and activity-related domains and questions for pediatric, adolescent, and adult patients with hemophilia B treated with rFIXFc prophylaxis. DESIGN: A post hoc analysis of data from a series of clinical trials. METHODS: This post hoc, long-term analysis assessed patient-reported outcomes (PROs) from the Kids B-LONG (NCT01440946: pediatric) and B-LONG (NCT01027364: adults and adolescents) parent studies and the B-YOND (NCT01425723: all age groups) extension study. RESULTS: Ninety-two adult and adolescent patients that started in the B-LONG study were assessed, with a median (range) duration of follow-up of 58.9 (0.0–78.4) months. The Haem-A-QoL total score was significantly reduced from baseline by 4.45 (p ⩽ 0.01), as were the subdomains ‘physical health’ (9.10; p = 0.001), ‘sports and leisure’ (11.25; p ⩽ 0.01), ‘treatment’ (2.69; p = 0.05), and ‘view of self’ (5.81; p = 0.002). Thirty pediatric patients that started in the Kids B-LONG study were assessed, with a median (min–max) duration of follow-up of 36.7 (9.0–59.9) months. The high level of satisfaction demonstrated by the PROs at baseline was maintained. CONCLUSION: rFIXFc prophylaxis reduced perceived pain and increased levels of physical activity with sustained, long-term improvements in QoL in adult and adolescent patients with hemophilia B and maintained high QoL scores in pediatric patients.
format Online
Article
Text
id pubmed-10240555
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-102405552023-06-06 Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: post hoc analysis of phase III trials using patient-reported outcomes Astermark, Jan Hermans, Cédric Ezzalfani, Monia Sidhom, Alaeddine Barbier, Sylvaine Kragh, Nana Falk, Aletta Eriksson, Daniel Ther Adv Hematol Original Research BACKGROUND: Pain is a common symptom of hemophilia that may adversely affect patients’ quality of life (QoL). Previous post hoc analyses of prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) have been published for adults and adolescents, demonstrating improvements in health-related QoL (HRQoL) when assessed by the haemophilia-specific QoL (HaemAQoL) questionnaire. OBJECTIVE: To describe in depth the evolution of QoL, pain- and activity-related domains and questions for pediatric, adolescent, and adult patients with hemophilia B treated with rFIXFc prophylaxis. DESIGN: A post hoc analysis of data from a series of clinical trials. METHODS: This post hoc, long-term analysis assessed patient-reported outcomes (PROs) from the Kids B-LONG (NCT01440946: pediatric) and B-LONG (NCT01027364: adults and adolescents) parent studies and the B-YOND (NCT01425723: all age groups) extension study. RESULTS: Ninety-two adult and adolescent patients that started in the B-LONG study were assessed, with a median (range) duration of follow-up of 58.9 (0.0–78.4) months. The Haem-A-QoL total score was significantly reduced from baseline by 4.45 (p ⩽ 0.01), as were the subdomains ‘physical health’ (9.10; p = 0.001), ‘sports and leisure’ (11.25; p ⩽ 0.01), ‘treatment’ (2.69; p = 0.05), and ‘view of self’ (5.81; p = 0.002). Thirty pediatric patients that started in the Kids B-LONG study were assessed, with a median (min–max) duration of follow-up of 36.7 (9.0–59.9) months. The high level of satisfaction demonstrated by the PROs at baseline was maintained. CONCLUSION: rFIXFc prophylaxis reduced perceived pain and increased levels of physical activity with sustained, long-term improvements in QoL in adult and adolescent patients with hemophilia B and maintained high QoL scores in pediatric patients. SAGE Publications 2023-05-29 /pmc/articles/PMC10240555/ /pubmed/37283819 http://dx.doi.org/10.1177/20406207231170701 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Astermark, Jan
Hermans, Cédric
Ezzalfani, Monia
Sidhom, Alaeddine
Barbier, Sylvaine
Kragh, Nana
Falk, Aletta
Eriksson, Daniel
Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: post hoc analysis of phase III trials using patient-reported outcomes
title Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: post hoc analysis of phase III trials using patient-reported outcomes
title_full Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: post hoc analysis of phase III trials using patient-reported outcomes
title_fullStr Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: post hoc analysis of phase III trials using patient-reported outcomes
title_full_unstemmed Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: post hoc analysis of phase III trials using patient-reported outcomes
title_short Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: post hoc analysis of phase III trials using patient-reported outcomes
title_sort recombinant factor ix fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia b: post hoc analysis of phase iii trials using patient-reported outcomes
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240555/
https://www.ncbi.nlm.nih.gov/pubmed/37283819
http://dx.doi.org/10.1177/20406207231170701
work_keys_str_mv AT astermarkjan recombinantfactorixfcprophylaxisreducespainandincreaseslevelsofphysicalactivitywithsustainedlongtermimprovementsinpatientswithhemophiliabposthocanalysisofphaseiiitrialsusingpatientreportedoutcomes
AT hermanscedric recombinantfactorixfcprophylaxisreducespainandincreaseslevelsofphysicalactivitywithsustainedlongtermimprovementsinpatientswithhemophiliabposthocanalysisofphaseiiitrialsusingpatientreportedoutcomes
AT ezzalfanimonia recombinantfactorixfcprophylaxisreducespainandincreaseslevelsofphysicalactivitywithsustainedlongtermimprovementsinpatientswithhemophiliabposthocanalysisofphaseiiitrialsusingpatientreportedoutcomes
AT sidhomalaeddine recombinantfactorixfcprophylaxisreducespainandincreaseslevelsofphysicalactivitywithsustainedlongtermimprovementsinpatientswithhemophiliabposthocanalysisofphaseiiitrialsusingpatientreportedoutcomes
AT barbiersylvaine recombinantfactorixfcprophylaxisreducespainandincreaseslevelsofphysicalactivitywithsustainedlongtermimprovementsinpatientswithhemophiliabposthocanalysisofphaseiiitrialsusingpatientreportedoutcomes
AT kraghnana recombinantfactorixfcprophylaxisreducespainandincreaseslevelsofphysicalactivitywithsustainedlongtermimprovementsinpatientswithhemophiliabposthocanalysisofphaseiiitrialsusingpatientreportedoutcomes
AT falkaletta recombinantfactorixfcprophylaxisreducespainandincreaseslevelsofphysicalactivitywithsustainedlongtermimprovementsinpatientswithhemophiliabposthocanalysisofphaseiiitrialsusingpatientreportedoutcomes
AT erikssondaniel recombinantfactorixfcprophylaxisreducespainandincreaseslevelsofphysicalactivitywithsustainedlongtermimprovementsinpatientswithhemophiliabposthocanalysisofphaseiiitrialsusingpatientreportedoutcomes